Titrating optimal dose of osmotic-controlled release oral delivery (OROS)-methylphenidate and its efficacy and safety in Korean children with ADHD: A multisite open labeled study

Psychiatry Investigation

Volumn 9, Issue 3, 2012, Pages 257-262

  Song, Dong Ho ^a   Choi, Soul ^a   Joung, Yoo Sook ^b   Ha, Eun Hye ^c   Kim, Boong Nyun ^d   Shin, Yee Jin ^a   Shin, Dongwon ^b   Yoo, Hee Jeong ^e   Cheon, Keun Ah ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sookmyung Women's University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

ADHD; Optimal dose; OROS MPH

Indexed keywords

METHYLPHENIDATE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED DRUG RELEASE; DEPRESSION; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; KOREA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; NIGHTMARE; OPEN STUDY; OPTIMAL DRUG DOSE; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; TIC; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84866666843     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2012.9.3.257     Document Type: Article

References (30)

1. Wilens TE, Bierderman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Ann Rev Med 2002;53:113-131.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association; 1994.
3. Barkley R, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up styudy. J Am Acad Child Adoles Psychiatry 1990;29:546-557.
4. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565-576.
5. Lilienfeld S, Waldman ID. The relation between childhood attentiondeficit hyperactivity disorder and adult antisocial behavior reexamined: the problem of heterogeneoity. Clin Psychol Rev 1990;10:699-725.
6. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S.
7. Horwitz SM, Kelleher K, Boyce T, Jensen P, Murphy M, Perrin E, et al. Barriers to health care research for children and youth with psychosocial problems. JAMA 2002;288:1508-1512.
8. Hoagwood K, Kelleher KJ, Feil M, Corner DM. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry 2000;39:198-206.
9. Leslie LK, Weckerly J, Landsverk J, Hough RL, Hurlburt MS, Wood PA. Racial/ethnic differences in the use of psychotropic medication in high-risk children and adolescents. J Am Acad Child Adolesc Psychiatry 2003;42:1433-1442.
10. Angold A, Costello EJ, Farmer EM, Burns BJ, Erkanli A. Impaired but undiagnosed. J Am Acad Child Adolesc Psychiatry 1999;38:129-137.
11. Bussing R, Gary FA, Mills TL, Garvan CW. Parental explanatory models of ADHD: gender and cultural variations. Soc Psychiatry Psychiatr Epidemiol 2003;38:563-575.
12. Zwirs BW, Burger H, Buitelaar JK, Schulpen TW. Ethnic differences in parental detection of externalizing disorders. Eur Child Adolesc Psychiatry 2006;15:418-426.
13. Greenhill L. Attention-deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin N Am 1995;4:123-168.
14. Service Hira. 2006 Health insurance review & assessment service. Seoul, Korea: 2006.
15. Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version-Korean version (K-SADSPL-K). Yonsei Med J 2004;45:81-89.
16. Swanson J. Remission vs. Response as the Goal of Therapy in ADHD. ADHD forum. Seoul; 2005.
17. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901.
18. So YK, Noh JS, Kim YS, Ko SG, Koh YJ. The relaibility and validity of Korean parent and teacher ADHD rating scale. J Korean Neuropsychiatr Assoc 2002;41:283-289.
19. Kim YS, So YK, Noh JS, Choi NK, Kim SJ, Koh YJ. Normative data on the Korean ADHD Rating Scales(K-ARS) for parents and teacher. J Korean Neuropsychiatr Assoc 2003;42:352-359.
20. Barkley RA, McMurray MB, Edelbrocks CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184192.
21. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Park MK, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:210-216.
22. Shin JY, Yang JW, Jang WS, Hong SD. Prescription status and efficacy of OROS-MPH and parent perception in children with ADHD: multicenter, observational study during 4 weeks. Korean J Psychopharmacol 2007;18:50-59.
23. Kim BS, Park EJ. An observational multi-center study for evaluation of efficacy, safety and parental satisfaction of methylphenidate-OROS I children with ADHD. Korean J Child Adolesc Psychiatry 2005;16:279-285.
24. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003;42:424-433.
25. Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, et al. Parmacokinetics of methylphenidate in preschoolers with attentiondeficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17:153-164.
26. Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin 2006;22:2557-2566.
27. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:351-356.
28. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hperctivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991;87:519-531.
29. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003;112:e404.
30. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90.